Back to results
US 2017/0360874 A1Published application
Combination formulation of three antiviral compounds
AssigneeGilead Pharmasset LLC
InventorsBen Chal, Elham Nejati, Rowchanak Pakdaman, Dimitrios Stefanidis
Life of this patent
Estimating the term…
Abstract
Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.
Claims82
A pharmaceutical composition comprising:
- a) an effective amount of velpatasvir having the formula:
- wherein velpatasvir is substantially amorphous;
- b) an effective amount of sofosbuvir having the formula:
- wherein sofosbuvir is substantially crystalline;
- and
- c) an effective amount of voxilaprevir having the formula:
- wherein voxilaprevir is substantially amorphous.
4 more elements
A pharmaceutical dosage form comprising:
- a) about 200 mg of a solid dispersion comprising velpatasvir dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer A, wherein velpatasvir is substantially amorphous;
- b) about 400 mg of sofosbuvir wherein sofosbuvir is substantially crystalline;
- and
- c) about 200 mg of a solid dispersion comprising voxilaprevir dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer B, wherein voxilaprevir is substantially amorphous,
- wherein polymer A and polymer B are each independently hypromellose, copovidone, povidone, or polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol, hydroxypropyl methylcellulose acetate-succinate, hydroxypropyl methylcellulose phthalate, or cellulose acetate phthalate.
2 more elements
A tablet, comprising:
- a) about 400 mg of sofosbuvir wherein sofosbuvir is substantially crystalline;
- b) about 200 mg of a solid dispersion comprising velpatasvir dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer A, wherein velpatasvir is substantially amorphous;
- and
- c) about 200 mg of a solid dispersion comprising voxilaprevir dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer B, wherein voxilaprevir is substantially amorphous,
- wherein polymer A and polymer B are each independently hypromellose, copovidone, povidone, or polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol, hydroxypropyl methylcellulose acetate-succinate, hydroxypropyl methylcellulose phthalate, or cellulose acetate phthalate.
2 more elements
Dependencies are inferred from the claim text.